#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=Protein
3-1	17-24	Protein	substance	new	coref	5-2

#Text=N-glycosylation is a critical post-translational modification , in which an oligosaccharide moiety is transferred from the glycosyl carrier dolichol-phosphate ( Dol-P ) and covalently attaches to a polypeptide chain via an asparagine residue .
4-1	25-40	N-glycosylation	abstract	new	coref	4-3[5_0]
4-2	41-43	is	_	_	_	_
4-3	44-45	a	abstract[5]	giv[5]	coref	6-3[21_5]
4-4	46-54	critical	abstract[5]	giv[5]	_	_
4-5	55-73	post-translational	abstract[5]	giv[5]	_	_
4-6	74-86	modification	abstract[5]	giv[5]	_	_
4-7	87-88	,	_	_	_	_
4-8	89-91	in	_	_	_	_
4-9	92-97	which	_	_	_	_
4-10	98-100	an	substance[7]	new[7]	_	_
4-11	101-116	oligosaccharide	abstract|substance[7]	new|new[7]	coref	5-5[18_0]
4-12	117-123	moiety	substance[7]	new[7]	_	_
4-13	124-126	is	_	_	_	_
4-14	127-138	transferred	_	_	_	_
4-15	139-143	from	_	_	_	_
4-16	144-147	the	person[10]	new[10]	_	_
4-17	148-156	glycosyl	abstract|person[10]	new|new[10]	_	_
4-18	157-164	carrier	organization|person[10]	new|new[10]	_	_
4-19	165-183	dolichol-phosphate	person[10]	new[10]	_	_
4-20	184-185	(	_	_	_	_
4-21	186-191	Dol-P	object	new	coref	9-21
4-22	192-193	)	_	_	_	_
4-23	194-197	and	_	_	_	_
4-24	198-208	covalently	_	_	_	_
4-25	209-217	attaches	_	_	_	_
4-26	218-220	to	_	_	_	_
4-27	221-222	a	abstract[13]	new[13]	coref	10-5[0_13]
4-28	223-234	polypeptide	place|abstract[13]	new|new[13]	_	_
4-29	235-240	chain	abstract[13]	new[13]	_	_
4-30	241-244	via	abstract[13]	new[13]	_	_
4-31	245-247	an	abstract[13]|object[15]	new[13]|new[15]	_	_
4-32	248-258	asparagine	abstract[13]|substance|object[15]	new[13]|new|new[15]	_	_
4-33	259-266	residue	abstract[13]|object[15]	new[13]|new[15]	_	_
4-34	267-268	.	_	_	_	_

#Text=Following protein conjugation , the oligosaccharide is further modified , increasing the functional and structural diversity of the proteome .
5-1	269-278	Following	_	_	_	_
5-2	279-286	protein	substance|abstract[17]	giv|new[17]	coref|coref	6-9|6-9
5-3	287-298	conjugation	abstract[17]	new[17]	_	_
5-4	299-300	,	_	_	_	_
5-5	301-304	the	abstract[18]	giv[18]	_	_
5-6	305-320	oligosaccharide	abstract[18]	giv[18]	_	_
5-7	321-323	is	_	_	_	_
5-8	324-331	further	_	_	_	_
5-9	332-340	modified	_	_	_	_
5-10	341-342	,	_	_	_	_
5-11	343-353	increasing	_	_	_	_
5-12	354-357	the	abstract[19]	new[19]	_	_
5-13	358-368	functional	abstract[19]	new[19]	_	_
5-14	369-372	and	abstract[19]	new[19]	_	_
5-15	373-383	structural	abstract[19]	new[19]	_	_
5-16	384-393	diversity	abstract[19]	new[19]	_	_
5-17	394-396	of	abstract[19]	new[19]	_	_
5-18	397-400	the	abstract[19]|object[20]	new[19]|new[20]	_	_
5-19	401-409	proteome	abstract[19]|object[20]	new[19]|new[20]	_	_
5-20	410-411	.	_	_	_	_

#Text=Indeed , this modification is crucial for proper protein folding , oligomerization , quality control , sorting , and transport .
6-1	412-418	Indeed	_	_	_	_
6-2	419-420	,	_	_	_	_
6-3	421-425	this	abstract[21]	giv[21]	_	_
6-4	426-438	modification	abstract[21]	giv[21]	_	_
6-5	439-441	is	_	_	_	_
6-6	442-449	crucial	_	_	_	_
6-7	450-453	for	_	_	_	_
6-8	454-460	proper	abstract[23]	new[23]	_	_
6-9	461-468	protein	substance|abstract[23]	giv|new[23]	coref	7-7
6-10	469-476	folding	abstract[23]	new[23]	_	_
6-11	477-478	,	_	_	_	_
6-12	479-494	oligomerization	place	new	_	_
6-13	495-496	,	_	_	_	_
6-14	497-504	quality	abstract[25]	new[25]	_	_
6-15	505-512	control	abstract[25]	new[25]	_	_
6-16	513-514	,	_	_	_	_
6-17	515-522	sorting	abstract	new	_	_
6-18	523-524	,	_	_	_	_
6-19	525-528	and	_	_	_	_
6-20	529-538	transport	abstract	new	_	_
6-21	539-540	.	_	_	_	_

#Text=Accordingly , even slight variations in protein glycosylation can markedly affect proteins structure and function and , thus , glycosylation disorders result in a wide range of clinical syndromes affecting practically every organ system .
7-1	541-552	Accordingly	_	_	_	_
7-2	553-554	,	_	_	_	_
7-3	555-559	even	abstract[28]	new[28]	_	_
7-4	560-566	slight	abstract[28]	new[28]	_	_
7-5	567-577	variations	abstract[28]	new[28]	_	_
7-6	578-580	in	abstract[28]	new[28]	_	_
7-7	581-588	protein	abstract[28]|substance|abstract[30]	new[28]|giv|new[30]	coref|coref|coref|coref	7-20[0_30]|14-10|7-20[0_30]|14-10
7-8	589-602	glycosylation	abstract[28]|abstract[30]	new[28]|new[30]	_	_
7-9	603-606	can	_	_	_	_
7-10	607-615	markedly	_	_	_	_
7-11	616-622	affect	_	_	_	_
7-12	623-631	proteins	substance|abstract[32]|abstract[33]	new|new[32]|new[33]	coref|coref|coref|coref|coref|coref	22-3[124_32]|22-3[125_33]|22-3[124_32]|22-3[125_33]|22-3[124_32]|22-3[125_33]
7-13	632-641	structure	abstract[32]|abstract[33]	new[32]|new[33]	_	_
7-14	642-645	and	abstract[33]	new[33]	_	_
7-15	646-654	function	abstract[33]|abstract	new[33]|new	_	_
7-16	655-658	and	_	_	_	_
7-17	659-660	,	_	_	_	_
7-18	661-665	thus	_	_	_	_
7-19	666-667	,	_	_	_	_
7-20	668-681	glycosylation	abstract	giv	coref	14-10[76_0]
7-21	682-691	disorders	abstract	new	_	_
7-22	692-698	result	_	_	_	_
7-23	699-701	in	_	_	_	_
7-24	702-703	a	abstract[37]	new[37]	_	_
7-25	704-708	wide	abstract[37]	new[37]	_	_
7-26	709-714	range	abstract[37]	new[37]	_	_
7-27	715-717	of	abstract[37]	new[37]	_	_
7-28	718-726	clinical	abstract[37]|abstract[38]	new[37]|new[38]	_	_
7-29	727-736	syndromes	abstract[37]|abstract[38]	new[37]|new[38]	_	_
7-30	737-746	affecting	_	_	_	_
7-31	747-758	practically	_	_	_	_
7-32	759-764	every	abstract[40]	new[40]	_	_
7-33	765-770	organ	abstract|abstract[40]	new|new[40]	_	_
7-34	771-777	system	abstract[40]	new[40]	_	_
7-35	778-779	.	_	_	_	_

#Text=Dehydrodolichyl diphosphate synthase ( DHDDS ) together with Nogo-B receptor ( NgBR ) form the human cis -prenyltransferase complex .
8-1	780-795	Dehydrodolichyl	abstract[42]	new[42]	coref	16-23[97_42]
8-2	796-807	diphosphate	person|abstract[42]	new|new[42]	coref	10-8[58_0]
8-3	808-816	synthase	abstract[42]	new[42]	_	_
8-4	817-818	(	_	_	_	_
8-5	819-824	DHDDS	place	new	coref	13-8
8-6	825-826	)	_	_	_	_
8-7	827-835	together	substance[45]	new[45]	_	_
8-8	836-840	with	substance[45]	new[45]	_	_
8-9	841-847	Nogo-B	abstract|substance[45]	new|new[45]	_	_
8-10	848-856	receptor	substance[45]	new[45]	_	_
8-11	857-858	(	_	_	_	_
8-12	859-863	NgBR	abstract	new	coref	13-18
8-13	864-865	)	_	_	_	_
8-14	866-870	form	event	new	coref|none	9-4[48_0]|8-14[0_48]
8-15	871-874	the	_	_	_	_
8-16	875-880	human	_	_	_	_
8-17	881-884	cis	_	_	_	_
8-18	885-903	-prenyltransferase	_	_	_	_
8-19	904-911	complex	_	_	_	_
8-20	912-913	.	_	_	_	_

#Text=This complex catalyzes the formation of dehydrodolichyl diphosphate ( DHDD ) , a long-chain polyprenyl serving as a precursor for Dol-P .
9-1	914-918	This	object[47]	new[47]	_	_
9-2	919-926	complex	object[47]	new[47]	_	_
9-3	927-936	catalyzes	_	_	_	_
9-4	937-940	the	event[48]	new[48]	_	_
9-5	941-950	formation	event[48]	new[48]	_	_
9-6	951-953	of	event[48]	new[48]	_	_
9-7	954-969	dehydrodolichyl	event[48]|abstract|abstract[50]	new[48]|new|new[50]	_	_
9-8	970-981	diphosphate	event[48]|abstract[50]	new[48]|new[50]	_	_
9-9	982-983	(	_	_	_	_
9-10	984-988	DHDD	place	new	coref	10-1
9-11	989-990	)	_	_	_	_
9-12	991-992	,	_	_	_	_
9-13	993-994	a	substance[52]	new[52]	_	_
9-14	995-1005	long-chain	substance[52]	new[52]	_	_
9-15	1006-1016	polyprenyl	substance[52]	new[52]	_	_
9-16	1017-1024	serving	_	_	_	_
9-17	1025-1027	as	_	_	_	_
9-18	1028-1029	a	_	_	_	_
9-19	1030-1039	precursor	_	_	_	_
9-20	1040-1043	for	_	_	_	_
9-21	1044-1049	Dol-P	substance	giv	_	_
9-22	1050-1051	.	_	_	_	_

#Text=DHDD is synthesized by chain elongation of farnesyl diphosphate ( FPP ) via multiple condensations with isopentenyl diphosphate ( IPP ) (
10-1	1052-1056	DHDD	abstract	giv	_	_
10-2	1057-1059	is	_	_	_	_
10-3	1060-1071	synthesized	_	_	_	_
10-4	1072-1074	by	_	_	_	_
10-5	1075-1080	chain	abstract|abstract[56]	giv|new[56]	_	_
10-6	1081-1091	elongation	abstract[56]	new[56]	_	_
10-7	1092-1094	of	abstract[56]	new[56]	_	_
10-8	1095-1103	farnesyl	abstract[56]|abstract|person[58]	new[56]|new|giv[58]	coref|coref	10-17[62_58]|10-17[62_58]
10-9	1104-1115	diphosphate	abstract[56]|person[58]	new[56]|giv[58]	_	_
10-10	1116-1117	(	_	_	_	_
10-11	1118-1121	FPP	substance	new	_	_
10-12	1122-1123	)	_	_	_	_
10-13	1124-1127	via	_	_	_	_
10-14	1128-1136	multiple	substance[60]	new[60]	_	_
10-15	1137-1150	condensations	substance[60]	new[60]	_	_
10-16	1151-1155	with	substance[60]	new[60]	_	_
10-17	1156-1167	isopentenyl	substance[60]|abstract|person[62]	new[60]|new|giv[62]	_	_
10-18	1168-1179	diphosphate	substance[60]|person[62]	new[60]|giv[62]	_	_
10-19	1180-1181	(	_	_	_	_
10-20	1182-1185	IPP	abstract	new	_	_
10-21	1186-1187	)	_	_	_	_
10-22	1188-1189	(	_	_	_	_

#Text=Figure 1
11-1	1190-1196	Figure	object[64]	new[64]	coref	20-1[121_64]
11-2	1197-1198	1	object[64]	new[64]	_	_

#Text=A ) .
12-1	1199-1200	A	_	_	_	_
12-2	1201-1202	)	_	_	_	_
12-3	1203-1204	.	_	_	_	_

#Text=Importantly , while previous studies revealed that DHDDS is required and sufficient for this catalytic activity , NgBR induces an increase in the expression and activity of the complex but exhibits no catalytic activity .
13-1	1205-1216	Importantly	_	_	_	_
13-2	1217-1218	,	_	_	_	_
13-3	1219-1224	while	_	_	_	_
13-4	1225-1233	previous	abstract[65]	new[65]	_	_
13-5	1234-1241	studies	abstract[65]	new[65]	_	_
13-6	1242-1250	revealed	_	_	_	_
13-7	1251-1255	that	_	_	_	_
13-8	1256-1261	DHDDS	place	giv	coref	14-8[74_0]
13-9	1262-1264	is	_	_	_	_
13-10	1265-1273	required	_	_	_	_
13-11	1274-1277	and	_	_	_	_
13-12	1278-1288	sufficient	_	_	_	_
13-13	1289-1292	for	_	_	_	_
13-14	1293-1297	this	abstract[67]	new[67]	coref	13-26[71_67]
13-15	1298-1307	catalytic	abstract[67]	new[67]	_	_
13-16	1308-1316	activity	abstract[67]	new[67]	_	_
13-17	1317-1318	,	_	_	_	_
13-18	1319-1323	NgBR	substance	giv	_	_
13-19	1324-1331	induces	_	_	_	_
13-20	1332-1334	an	event[69]	new[69]	_	_
13-21	1335-1343	increase	event[69]	new[69]	_	_
13-22	1344-1346	in	event[69]	new[69]	_	_
13-23	1347-1350	the	event[69]|abstract[70]	new[69]|new[70]	_	_
13-24	1351-1361	expression	event[69]|abstract[70]	new[69]|new[70]	_	_
13-25	1362-1365	and	event[69]	new[69]	_	_
13-26	1366-1374	activity	event[69]|abstract[71]	new[69]|giv[71]	coref	13-32[72_71]
13-27	1375-1377	of	event[69]|abstract[71]	new[69]|giv[71]	_	_
13-28	1378-1381	the	event[69]|abstract[71]	new[69]|giv[71]	_	_
13-29	1382-1389	complex	event[69]|abstract[71]	new[69]|giv[71]	_	_
13-30	1390-1393	but	_	_	_	_
13-31	1394-1402	exhibits	_	_	_	_
13-32	1403-1405	no	abstract[72]	giv[72]	_	_
13-33	1406-1415	catalytic	abstract[72]	giv[72]	_	_
13-34	1416-1424	activity	abstract[72]	giv[72]	_	_
13-35	1425-1426	.	_	_	_	_

#Text=In line with the important role of DHDDS in protein glycosylation , mutations in DHDDS were recently shown to cause autosomal recessive retinitis pigmentosa , a fatal glycosylation disorder , and developmental epileptic encephalopathies .
14-1	1427-1429	In	_	_	_	_
14-2	1430-1434	line	_	_	_	_
14-3	1435-1439	with	_	_	_	_
14-4	1440-1443	the	abstract[73]	new[73]	coref	22-6[126_73]
14-5	1444-1453	important	abstract[73]	new[73]	_	_
14-6	1454-1458	role	abstract[73]	new[73]	_	_
14-7	1459-1461	of	abstract[73]	new[73]	_	_
14-8	1462-1467	DHDDS	abstract[73]|place[74]	new[73]|giv[74]	coref	14-15[0_74]
14-9	1468-1470	in	abstract[73]|place[74]	new[73]|giv[74]	_	_
14-10	1471-1478	protein	abstract[73]|place[74]|substance|abstract[76]	new[73]|giv[74]|giv|giv[76]	coref|coref	14-28[0_76]|14-28[0_76]
14-11	1479-1492	glycosylation	abstract[73]|place[74]|abstract[76]	new[73]|giv[74]|giv[76]	_	_
14-12	1493-1494	,	_	_	_	_
14-13	1495-1504	mutations	abstract[77]	new[77]	_	_
14-14	1505-1507	in	abstract[77]	new[77]	_	_
14-15	1508-1513	DHDDS	abstract[77]|abstract	new[77]|giv	coref	15-6
14-16	1514-1518	were	_	_	_	_
14-17	1519-1527	recently	_	_	_	_
14-18	1528-1533	shown	_	_	_	_
14-19	1534-1536	to	_	_	_	_
14-20	1537-1542	cause	_	_	_	_
14-21	1543-1552	autosomal	animal	new	_	_
14-22	1553-1562	recessive	object[81]	new[81]	_	_
14-23	1563-1572	retinitis	abstract|object[81]	new|new[81]	_	_
14-24	1573-1583	pigmentosa	object[81]	new[81]	_	_
14-25	1584-1585	,	_	_	_	_
14-26	1586-1587	a	abstract[83]	new[83]	_	_
14-27	1588-1593	fatal	abstract[83]	new[83]	_	_
14-28	1594-1607	glycosylation	abstract|abstract[83]	giv|new[83]	_	_
14-29	1608-1616	disorder	abstract[83]	new[83]	_	_
14-30	1617-1618	,	_	_	_	_
14-31	1619-1622	and	_	_	_	_
14-32	1623-1636	developmental	abstract[84]	new[84]	_	_
14-33	1637-1646	epileptic	abstract[84]	new[84]	_	_
14-34	1647-1663	encephalopathies	abstract[84]	new[84]	_	_
14-35	1664-1665	.	_	_	_	_

#Text=Despite the clinical importance of DHDDS , it was not structurally and functionally characterized to date .
15-1	1666-1673	Despite	_	_	_	_
15-2	1674-1677	the	abstract[85]	new[85]	_	_
15-3	1678-1686	clinical	abstract[85]	new[85]	_	_
15-4	1687-1697	importance	abstract[85]	new[85]	_	_
15-5	1698-1700	of	abstract[85]	new[85]	_	_
15-6	1701-1706	DHDDS	abstract[85]|abstract	new[85]|giv	ana	15-8
15-7	1707-1708	,	_	_	_	_
15-8	1709-1711	it	abstract	giv	coref	16-13
15-9	1712-1715	was	_	_	_	_
15-10	1716-1719	not	_	_	_	_
15-11	1720-1732	structurally	_	_	_	_
15-12	1733-1736	and	_	_	_	_
15-13	1737-1749	functionally	_	_	_	_
15-14	1750-1763	characterized	_	_	_	_
15-15	1764-1766	to	_	_	_	_
15-16	1767-1771	date	time	new	_	_
15-17	1772-1773	.	_	_	_	_

#Text=Conserved domains search analysis reveals that the cis -prenyltransferase catalytic domain of DHDDS ( residues 24 – 248 ) is homologous to undecaprenyl pyrophosphate synthase ( UPPS ) , a well characterized bacterial cis -prenyltransferase .
16-1	1774-1783	Conserved	abstract[89]	new[89]	coref	18-20[115_89]
16-2	1784-1791	domains	abstract[89]	new[89]	_	_
16-3	1792-1798	search	_	_	_	_
16-4	1799-1807	analysis	abstract	new	_	_
16-5	1808-1815	reveals	_	_	_	_
16-6	1816-1820	that	_	_	_	_
16-7	1821-1824	the	abstract[91]	new[91]	appos	16-15[93_91]
16-8	1825-1828	cis	abstract[91]	new[91]	_	_
16-9	1829-1847	-prenyltransferase	abstract[91]	new[91]	_	_
16-10	1848-1857	catalytic	abstract[91]	new[91]	_	_
16-11	1858-1864	domain	abstract[91]	new[91]	_	_
16-12	1865-1867	of	abstract[91]	new[91]	_	_
16-13	1868-1873	DHDDS	abstract[91]|place	new[91]|giv	coref	18-14[114_0]
16-14	1874-1875	(	_	_	_	_
16-15	1876-1884	residues	abstract[93]	giv[93]	coref	17-9[103_93]
16-16	1885-1887	24	abstract[93]	giv[93]	_	_
16-17	1888-1889	–	abstract[93]	giv[93]	_	_
16-18	1890-1893	248	abstract[93]|quantity	giv[93]|new	_	_
16-19	1894-1895	)	_	_	_	_
16-20	1896-1898	is	_	_	_	_
16-21	1899-1909	homologous	_	_	_	_
16-22	1910-1912	to	_	_	_	_
16-23	1913-1925	undecaprenyl	abstract|abstract[97]	new|giv[97]	appos|appos	16-27[0_97]|16-27[0_97]
16-24	1926-1939	pyrophosphate	person|abstract[97]	new|giv[97]	_	_
16-25	1940-1948	synthase	abstract[97]	giv[97]	_	_
16-26	1949-1950	(	_	_	_	_
16-27	1951-1955	UPPS	abstract	giv	coref	24-5[133_0]
16-28	1956-1957	)	_	_	_	_
16-29	1958-1959	,	_	_	_	_
16-30	1960-1961	a	object[100]	new[100]	_	_
16-31	1962-1966	well	object[100]	new[100]	_	_
16-32	1967-1980	characterized	object[100]	new[100]	_	_
16-33	1981-1990	bacterial	substance|object[100]	new|new[100]	coref	24-3[132_0]
16-34	1991-1994	cis	object[100]	new[100]	_	_
16-35	1995-2013	-prenyltransferase	object[100]	new[100]	_	_
16-36	2014-2015	.	_	_	_	_

#Text=Consisting of seven α-helices and six β-strands , this domain forms dimers , with a hydrophobic catalytic tunnel surrounded by two α-helices and four β−strands within each monomer .
17-1	2016-2026	Consisting	_	_	_	_
17-2	2027-2029	of	_	_	_	_
17-3	2030-2035	seven	quantity[101]	new[101]	_	_
17-4	2036-2045	α-helices	quantity[101]	new[101]	_	_
17-5	2046-2049	and	_	_	_	_
17-6	2050-2053	six	place[102]	new[102]	_	_
17-7	2054-2063	β-strands	place[102]	new[102]	_	_
17-8	2064-2065	,	_	_	_	_
17-9	2066-2070	this	abstract[103]	giv[103]	coref	18-4[112_103]
17-10	2071-2077	domain	abstract[103]	giv[103]	_	_
17-11	2078-2083	forms	_	_	_	_
17-12	2084-2090	dimers	object	new	_	_
17-13	2091-2092	,	_	_	_	_
17-14	2093-2097	with	_	_	_	_
17-15	2098-2099	a	object[105]	new[105]	_	_
17-16	2100-2111	hydrophobic	object[105]	new[105]	_	_
17-17	2112-2121	catalytic	object[105]	new[105]	_	_
17-18	2122-2128	tunnel	object[105]	new[105]	_	_
17-19	2129-2139	surrounded	_	_	_	_
17-20	2140-2142	by	_	_	_	_
17-21	2143-2146	two	substance[106]	new[106]	_	_
17-22	2147-2156	α-helices	substance[106]	new[106]	_	_
17-23	2157-2160	and	_	_	_	_
17-24	2161-2165	four	substance[107]	new[107]	_	_
17-25	2166-2175	β−strands	substance[107]	new[107]	_	_
17-26	2176-2182	within	substance[107]	new[107]	_	_
17-27	2183-2187	each	substance[107]|object[108]	new[107]|new[108]	_	_
17-28	2188-2195	monomer	substance[107]|object[108]	new[107]|new[108]	_	_
17-29	2196-2197	.	_	_	_	_

#Text=In contrast with the N-terminal cis -prenyltransferase homology domain , the C-terminus of human DHDDS does not converge with any known conserved domains .
18-1	2198-2200	In	_	_	_	_
18-2	2201-2209	contrast	abstract[109]	new[109]	_	_
18-3	2210-2214	with	abstract[109]	new[109]	_	_
18-4	2215-2218	the	abstract[109]|abstract[112]	new[109]|giv[112]	coref	19-10[118_112]
18-5	2219-2229	N-terminal	abstract[109]|place|abstract[112]	new[109]|new|giv[112]	_	_
18-6	2230-2233	cis	abstract[109]|abstract[112]	new[109]|giv[112]	_	_
18-7	2234-2252	-prenyltransferase	abstract[109]|abstract[112]	new[109]|giv[112]	_	_
18-8	2253-2261	homology	abstract[109]|abstract|abstract[112]	new[109]|new|giv[112]	_	_
18-9	2262-2268	domain	abstract[109]|abstract[112]	new[109]|giv[112]	_	_
18-10	2269-2270	,	_	_	_	_
18-11	2271-2274	the	abstract[113]	new[113]	_	_
18-12	2275-2285	C-terminus	abstract[113]	new[113]	_	_
18-13	2286-2288	of	abstract[113]	new[113]	_	_
18-14	2289-2294	human	abstract[113]|place[114]	new[113]|giv[114]	coref	23-14[131_114]
18-15	2295-2300	DHDDS	abstract[113]|place[114]	new[113]|giv[114]	_	_
18-16	2301-2305	does	_	_	_	_
18-17	2306-2309	not	_	_	_	_
18-18	2310-2318	converge	_	_	_	_
18-19	2319-2323	with	_	_	_	_
18-20	2324-2327	any	abstract[115]	giv[115]	_	_
18-21	2328-2333	known	abstract[115]	giv[115]	_	_
18-22	2334-2343	conserved	abstract[115]	giv[115]	_	_
18-23	2344-2351	domains	abstract[115]	giv[115]	_	_
18-24	2352-2353	.	_	_	_	_

#Text=Intriguingly , despite the low level of conservation , a C-terminal domain is common to long-chain cis -prenyltransferases and is absent in short- and medium-chain cis -prenyltransferases (
19-1	2354-2366	Intriguingly	_	_	_	_
19-2	2367-2368	,	_	_	_	_
19-3	2369-2376	despite	_	_	_	_
19-4	2377-2380	the	abstract[116]	new[116]	_	_
19-5	2381-2384	low	abstract[116]	new[116]	_	_
19-6	2385-2390	level	abstract[116]	new[116]	_	_
19-7	2391-2393	of	abstract[116]	new[116]	_	_
19-8	2394-2406	conservation	abstract[116]|abstract	new[116]|new	_	_
19-9	2407-2408	,	_	_	_	_
19-10	2409-2410	a	abstract[118]	giv[118]	_	_
19-11	2411-2421	C-terminal	abstract[118]	giv[118]	_	_
19-12	2422-2428	domain	abstract[118]	giv[118]	_	_
19-13	2429-2431	is	_	_	_	_
19-14	2432-2438	common	_	_	_	_
19-15	2439-2441	to	_	_	_	_
19-16	2442-2452	long-chain	object[119]	new[119]	coref	19-23[120_119]
19-17	2453-2456	cis	object[119]	new[119]	_	_
19-18	2457-2476	-prenyltransferases	object[119]	new[119]	_	_
19-19	2477-2480	and	_	_	_	_
19-20	2481-2483	is	_	_	_	_
19-21	2484-2490	absent	_	_	_	_
19-22	2491-2493	in	_	_	_	_
19-23	2494-2500	short-	object[120]	giv[120]	_	_
19-24	2501-2504	and	object[120]	giv[120]	_	_
19-25	2505-2517	medium-chain	object[120]	giv[120]	_	_
19-26	2518-2521	cis	object[120]	giv[120]	_	_
19-27	2522-2541	-prenyltransferases	object[120]	giv[120]	_	_
19-28	2542-2543	(	_	_	_	_

#Text=Figure 1
20-1	2544-2550	Figure	object[121]	giv[121]	ana	22-3[0_121]
20-2	2551-2552	1	object[121]	giv[121]	_	_

#Text=B ) .
21-1	2553-2554	B	person	new	_	_
21-2	2555-2556	)	_	_	_	_
21-3	2557-2558	.	_	_	_	_

#Text=Nevertheless , its structure and functional role remains elusive .
22-1	2559-2571	Nevertheless	_	_	_	_
22-2	2572-2573	,	_	_	_	_
22-3	2574-2577	its	object|abstract[124]|abstract[125]	giv|giv[124]|giv[125]	_	_
22-4	2578-2587	structure	abstract[124]|abstract[125]	giv[124]|giv[125]	_	_
22-5	2588-2591	and	abstract[125]	giv[125]	_	_
22-6	2592-2602	functional	abstract[125]|abstract[126]	giv[125]|giv[126]	_	_
22-7	2603-2607	role	abstract[125]|abstract[126]	giv[125]|giv[126]	_	_
22-8	2608-2615	remains	_	_	_	_
22-9	2616-2623	elusive	_	_	_	_
22-10	2624-2625	.	_	_	_	_

#Text=Recently , we have devised an efficient procedure for overexpression and purification of human DHDDS in Escherichia coli .
23-1	2626-2634	Recently	_	_	_	_
23-2	2635-2636	,	_	_	_	_
23-3	2637-2639	we	person	acc	ana	24-8
23-4	2640-2644	have	_	_	_	_
23-5	2645-2652	devised	_	_	_	_
23-6	2653-2655	an	abstract[128]	new[128]	_	_
23-7	2656-2665	efficient	abstract[128]	new[128]	_	_
23-8	2666-2675	procedure	abstract[128]	new[128]	_	_
23-9	2676-2679	for	abstract[128]	new[128]	_	_
23-10	2680-2694	overexpression	abstract[128]|abstract	new[128]|new	_	_
23-11	2695-2698	and	abstract[128]	new[128]	_	_
23-12	2699-2711	purification	abstract[128]|event[130]	new[128]|new[130]	_	_
23-13	2712-2714	of	abstract[128]|event[130]	new[128]|new[130]	_	_
23-14	2715-2720	human	abstract[128]|event[130]|place[131]	new[128]|new[130]|giv[131]	coref	24-11[135_131]
23-15	2721-2726	DHDDS	abstract[128]|event[130]|place[131]	new[128]|new[130]|giv[131]	_	_
23-16	2727-2729	in	abstract[128]|event[130]|place[131]	new[128]|new[130]|giv[131]	_	_
23-17	2730-2741	Escherichia	abstract[128]|event[130]|place[131]	new[128]|new[130]|giv[131]	_	_
23-18	2742-2746	coli	abstract[128]|event[130]|place[131]	new[128]|new[130]|giv[131]	_	_
23-19	2747-2748	.	_	_	_	_

#Text=Similar to the bacterial homolog UPPS , we showed that human DHDDS forms active homodimers .
24-1	2749-2756	Similar	_	_	_	_
24-2	2757-2759	to	_	_	_	_
24-3	2760-2763	the	substance[132]	giv[132]	_	_
24-4	2764-2773	bacterial	substance[132]	giv[132]	_	_
24-5	2774-2781	homolog	abstract[133]	giv[133]	_	_
24-6	2782-2786	UPPS	abstract[133]	giv[133]	_	_
24-7	2787-2788	,	_	_	_	_
24-8	2789-2791	we	person	giv	ana	26-3
24-9	2792-2798	showed	_	_	_	_
24-10	2799-2803	that	_	_	_	_
24-11	2804-2809	human	abstract[135]	giv[135]	coref	26-12[0_135]
24-12	2810-2815	DHDDS	abstract[135]	giv[135]	_	_
24-13	2816-2821	forms	_	_	_	_
24-14	2822-2828	active	object[136]	new[136]	_	_
24-15	2829-2839	homodimers	object[136]	new[136]	_	_
24-16	2840-2841	.	_	_	_	_

#Text=However , the molecular details of the interaction interface and the overall architecture of the enzyme remained obscure .
25-1	2842-2849	However	_	_	_	_
25-2	2850-2851	,	_	_	_	_
25-3	2852-2855	the	abstract[137]	new[137]	_	_
25-4	2856-2865	molecular	abstract[137]	new[137]	_	_
25-5	2866-2873	details	abstract[137]	new[137]	_	_
25-6	2874-2876	of	abstract[137]	new[137]	_	_
25-7	2877-2880	the	abstract[137]|abstract[139]	new[137]|new[139]	_	_
25-8	2881-2892	interaction	abstract[137]|abstract|abstract[139]	new[137]|new|new[139]	_	_
25-9	2893-2902	interface	abstract[137]|abstract[139]	new[137]|new[139]	_	_
25-10	2903-2906	and	abstract[137]	new[137]	_	_
25-11	2907-2910	the	abstract[137]|abstract[140]	new[137]|new[140]	_	_
25-12	2911-2918	overall	abstract[137]|abstract[140]	new[137]|new[140]	_	_
25-13	2919-2931	architecture	abstract[137]|abstract[140]	new[137]|new[140]	_	_
25-14	2932-2934	of	abstract[137]|abstract[140]	new[137]|new[140]	_	_
25-15	2935-2938	the	abstract[137]|abstract[140]|object[141]	new[137]|new[140]|new[141]	coref	26-28[0_141]
25-16	2939-2945	enzyme	abstract[137]|abstract[140]|object[141]	new[137]|new[140]|new[141]	_	_
25-17	2946-2954	remained	_	_	_	_
25-18	2955-2962	obscure	_	_	_	_
25-19	2963-2964	.	_	_	_	_

#Text=Here , we determine a structural model for the full-length human DHDDS homodimer using an integrative approach that combines multiple sources of information , including a radioligand-based enzyme kinetics assay , size-exclusion chromatography multi-angle light scattering ( SEC-MALS ) , small-angle X-ray scattering ( SAXS ) , and hydrogen – deuterium exchange mass-spectrometry ( HDX-MS ) .
26-1	2965-2969	Here	_	_	_	_
26-2	2970-2971	,	_	_	_	_
26-3	2972-2974	we	person	giv	_	_
26-4	2975-2984	determine	_	_	_	_
26-5	2985-2986	a	object[143]	new[143]	_	_
26-6	2987-2997	structural	object[143]	new[143]	_	_
26-7	2998-3003	model	object[143]	new[143]	_	_
26-8	3004-3007	for	object[143]	new[143]	_	_
26-9	3008-3011	the	object[143]|object[145]	new[143]|new[145]	_	_
26-10	3012-3023	full-length	object[143]|object[145]	new[143]|new[145]	_	_
26-11	3024-3029	human	object[143]|object[145]	new[143]|new[145]	_	_
26-12	3030-3035	DHDDS	object[143]|abstract|object[145]	new[143]|giv|new[145]	_	_
26-13	3036-3045	homodimer	object[143]|object[145]	new[143]|new[145]	_	_
26-14	3046-3051	using	_	_	_	_
26-15	3052-3054	an	abstract[146]	new[146]	_	_
26-16	3055-3066	integrative	abstract[146]	new[146]	_	_
26-17	3067-3075	approach	abstract[146]	new[146]	_	_
26-18	3076-3080	that	_	_	_	_
26-19	3081-3089	combines	_	_	_	_
26-20	3090-3098	multiple	abstract[147]	new[147]	_	_
26-21	3099-3106	sources	abstract[147]	new[147]	_	_
26-22	3107-3109	of	abstract[147]	new[147]	_	_
26-23	3110-3121	information	abstract[147]|abstract	new[147]|new	_	_
26-24	3122-3123	,	abstract[147]	new[147]	_	_
26-25	3124-3133	including	abstract[147]	new[147]	_	_
26-26	3134-3135	a	abstract[147]|abstract[151]	new[147]|new[151]	_	_
26-27	3136-3153	radioligand-based	abstract[147]|abstract[151]	new[147]|new[151]	_	_
26-28	3154-3160	enzyme	abstract[147]|object|abstract[151]	new[147]|giv|new[151]	_	_
26-29	3161-3169	kinetics	abstract[147]|abstract|abstract[151]	new[147]|new|new[151]	_	_
26-30	3170-3175	assay	abstract[147]|abstract[151]	new[147]|new[151]	_	_
26-31	3176-3177	,	abstract[147]	new[147]	_	_
26-32	3178-3192	size-exclusion	abstract[147]|object|abstract[155]	new[147]|new|new[155]	_	_
26-33	3193-3207	chromatography	abstract[147]|object|abstract[155]	new[147]|new|new[155]	_	_
26-34	3208-3219	multi-angle	abstract[147]|abstract[155]	new[147]|new[155]	_	_
26-35	3220-3225	light	abstract[147]|object|abstract[155]	new[147]|new|new[155]	_	_
26-36	3226-3236	scattering	abstract[147]|abstract[155]	new[147]|new[155]	_	_
26-37	3237-3238	(	abstract[147]	new[147]	_	_
26-38	3239-3247	SEC-MALS	abstract[147]|object	new[147]|new	_	_
26-39	3248-3249	)	abstract[147]	new[147]	_	_
26-40	3250-3251	,	abstract[147]	new[147]	_	_
26-41	3252-3263	small-angle	abstract[147]|abstract[158]	new[147]|new[158]	appos	26-45[0_158]
26-42	3264-3269	X-ray	abstract[147]|object|abstract[158]	new[147]|new|new[158]	_	_
26-43	3270-3280	scattering	abstract[147]|abstract[158]	new[147]|new[158]	_	_
26-44	3281-3282	(	abstract[147]	new[147]	_	_
26-45	3283-3287	SAXS	abstract[147]|abstract	new[147]|giv	_	_
26-46	3288-3289	)	abstract[147]	new[147]	_	_
26-47	3290-3291	,	abstract[147]	new[147]	_	_
26-48	3292-3295	and	abstract[147]	new[147]	_	_
26-49	3296-3304	hydrogen	abstract[147]|abstract	new[147]|new	appos	26-51[163_0]
26-50	3305-3306	–	_	_	_	_
26-51	3307-3316	deuterium	substance|abstract[163]	new|giv[163]	appos|appos	26-55[0_163]|26-55[0_163]
26-52	3317-3325	exchange	event|abstract[163]	new|giv[163]	_	_
26-53	3326-3343	mass-spectrometry	abstract[163]	giv[163]	_	_
26-54	3344-3345	(	_	_	_	_
26-55	3346-3352	HDX-MS	abstract	giv	_	_
26-56	3353-3354	)	_	_	_	_
26-57	3355-3356	.	_	_	_	_
